8-K: Aethlon Medical Announces 1-for-10 Reverse Stock Split

Aethlon Medical, Inc. will implement a 1-for-10 reverse stock split to manage dilution and maintain Nasdaq listing compliance, effective October 16, 2025.

Summary

• Aethlon Medical, Inc. filed a Certificate of Change on October 14, 2025, authorizing a 1-for-10 reverse stock split of its common stock.
• The reverse stock split will become effective at 10:00 am Eastern Time on October 16, 2025.
• Common Stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market on October 20, 2025, under the existing symbol AEMD.
• The primary reasons for the reverse stock split are to support the company's overall capital-markets and operating plan, manage dilution, and ensure continued compliance with Nasdaq Listing Rule 5550(a)(2).
• No fractional shares will be issued; stockholders who would otherwise receive a fractional share will receive one whole share of post-split common stock.
• The company's authorized shares of common stock will decrease from 60,000,000 to 6,000,000.
• As of October 16, 2025, outstanding common stock will reduce from 7,612,106 shares to approximately 761,210 shares (subject to fractional share adjustments).
• Stockholder approval was not required under Nevada law, as the split does not adversely affect other stock classes and no cash/scrip is issued for fractional shares.
• The par value of the common stock, $0.001 per share, remains unchanged.
• All outstanding options, warrants, and convertible securities will be appropriately adjusted.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the company is proactively addressing a critical compliance issue (Nasdaq listing) and managing its capital structure. While reverse splits can sometimes signal underlying challenges, this action is presented as a strategic move to support future plans and maintain market access.

Positives

• The reverse stock split is intended to ensure continued compliance with Nasdaq Listing Rule 5550(a)(2), preventing potential delisting.
• It is part of the company's overall capital-markets and operating plan, aiming for better dilution management.
• The proportional ownership interest and voting power of stockholders will remain virtually unchanged, except for minor adjustments from rounding fractional shares.

Negatives

• Reverse stock splits can sometimes be perceived negatively by the market, potentially signaling underlying financial challenges or a low stock price.
• The reduction in the number of outstanding shares could potentially lead to decreased trading liquidity, although the filing does not explicitly state this as a negative.

Risks

• Failure to maintain compliance with Nasdaq Listing Rule 5550(a)(2) could lead to delisting, which the reverse stock split aims to mitigate.

Future Outlook

The company anticipates that the reverse stock split will support its ongoing capital-markets and operating plan, ensuring continued compliance with Nasdaq listing requirements and facilitating dilution management.

Management Comments

• The reverse stock split is being effectuated as a part of the company's overall capital-markets and operating plan, including dilution management and continued compliance with Nasdaq Listing Rule 5550(a)(2).

Industry Context

Reverse stock splits are a common corporate action, particularly for companies listed on exchanges like Nasdaq, to meet minimum bid price requirements and avoid delisting. This move by Aethlon Medical aligns with typical strategies employed by companies facing similar compliance challenges, aiming to improve stock price per share and market perception.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism used by publicly traded companies to increase their share price to meet exchange listing requirements, such as Nasdaq's minimum bid price rule. Many companies, including those in the biotechnology and medical device sectors, have historically undertaken similar actions to maintain their listing status.
• The 1-for-10 ratio is a common consolidation factor, often chosen to achieve a significant increase in per-share price without being overly aggressive, which could deter investors.
• The provision to round up fractional shares to whole shares is a shareholder-friendly approach, avoiding cash payments for small fractions and simplifying the process for investors.

Stakeholder Impact

• Shareholders will hold fewer shares, but their proportional ownership interest and voting power in the company will remain virtually unchanged.
• The per-share price of the common stock is expected to increase proportionally, potentially improving market perception and meeting Nasdaq listing requirements.

Next Steps

• Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market on October 20, 2025.
• All outstanding options, warrants, and convertible securities will be adjusted to reflect the reverse stock split.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to maintain Nasdaq listing compliance and manage the capital structure. It does not fundamentally alter the company's business operations or financial performance in the short term. While it addresses a potential negative (delisting), it doesn't present new catalysts for significant growth or decline. Therefore, a 'hold' recommendation is appropriate for investors to observe the company's operational progress post-split.

Keywords

AEMD, reverse stock split, Nasdaq compliance, capital markets, common stock, share consolidation, dilution management, corporate action